The burgeoning popularity of retatrutide, initially for blood sugar control , is creating significant interest within the UK , prompting a notable shift in peptide trends. Availability these treatments remains a complex situation , with NHS provision currently limited and specialist practices offering treatment at a higher cost . Concerns are being